

## THIR BOUNDS WARROW DEWINDER OF A

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

**United States Patent and Trademark Office** 



May 03, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/477,909

FILING DATE: June 12, 2003

DA 1164870

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN COMPLIANCE WITH RULE 17.1(a) OR (b)

REC'D 2 4 JUN 2004

WIPO PCT

By Authority of the

COMMISSIONER OF PATENTS AND TRADEMARKS

L. Edeler

L. EDELEN
Certifying Officer

#### EXPRESS MAIL NO. EV348171815US

PTO/SB/16 (02-01)

Approved for use through 10/31/2002, OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

\*\*PROVISIONAL APPLICATION FOR PATENT ONLY CONTROL OF THE PROPERTY OF THE PROPERT

#### PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).

-,		1N	IVENTOR(S)				
Given Name (first and middle [if any])		Family N	Name or Surnan	ne (City and	Residence (City and either State or Foreign Country)		
Karl		Α	ndersson		Uppsala, Sweden		
Christin	na		Wass		Uppsala, Sv	veden	
Additional inventor	Additional inventors are being named on the separately numbered sheets attached hereto						
<del></del>		·····	ENTION (500 cf				
METH	OD AND APPARA	ATUS FOR	CHARACTE	RIZATION OF II	NTERACTION		
Direct all correspondence	CORRESPONDEN	ICE ADDR	RESS				
Customer Number				<del></del>	1 (161) (161) 1 (161)	)500	
OR .	Type Custo	mer Numbe	er here		• •	ADEMARK OFFICE	
City			State		ZIP		
Country			Telephone		Fax		
	ENCLOSED	APPLICAT	ION PARTS (cf	eck all that apply	y)	·	
∑ Specification Nu	mber of Pages		27	CD(s), Numbe	r		
Drawing(s) Num	ber of Sheets		10 🛚 🗵	Other (specify)	Fee Transi	nittal (+ copy)	
Application Data	a Sheet. See 37 CF	R 1.76		<del></del>			
METHOD OF PAYMENT	OF FILING FEES FO	R THIS PR	OVISIONAL AP	PLICATION FOR	PATENT		
Applicant claims sm	all entity status. S	ee 37 CFF	R 1.27.				
A check or money of fees.	order for \$ <u>160</u> is en	closed to d	cover the filing				
The Commissioner fees to Deposit Acc		ed to charg	je filing	19-1090			
The Commissioner or credit any overpa	is hereby authorize	ed to charg	e any deficien	<del></del>	<del></del>		
				13-1030			
Payment by credit card. Form PTO-2038 is attached.  The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.							
No.							
Yes, the name of the U.S. Government agency and the Government contract number are:							
Respectfully submitted,				<del></del>			
SIGNATURE			DATE		June 12, 20	03	
TYPED or PRINTED NAME	Karl R. Hermann	ns	REGIST (if appro	RATION NO. priate)	33,507		
TELEPHONE	(206) 622-4900		DOCKE	T NUMBER:	740073.465	P1	

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chilol Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C., 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mall Step Provisional Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

D:\740073.465P1 \390512\_1.DOC

EXPRESS MAIL NO. EV348171815US PT0/SB/17 (01-03) Approved for use through 04/30/2003, OMB 0651-0032

	Complete if Known			
FEE TRANSMITTAL	Application Number			
for FY 2003	Filing Date	June 12, 2003		
	First Named Inventor	Karl Andersson		
Patent fees are subject to annual revision.	Examiner Name			
Applicant claims small entity status. See 37 CFR 1.27.	Group Art Unit			
TOTAL AMOUNT OF PAYMENT (\$) 160	Attorney Docket No.	740073.465P1		

Payment Enclosed:    Check   Credit card   Money Order   Other	METHOD OF PATMENT						
Deposit Account:  Deposit Account   19-1090    Number   Deposit Account   PLLC    The Commissioner is authorized to (check all that apply)  Charge fee(s) indicated below   Credit any overpayments   Charge any additional fee(s) during the pendency of this application   Charge fee(s) Indicated below, oxcopt for the filling fee   Charge any deficiencies   Charge any deficiencies   Description   Fee   Description   Fee   Description   Paid   Description   Paid   Description   Paid   Description   Paid   Description   Descript							
Deposit Account Number  Deposit Account Name  Deposit Account Name  Deposit Account Name  Charge fee(s) indicated below Credit any overpayments  Charge any additional fee(s) during the pendency of this application  Charge any deficiencies  to the above-identified deposit account.  FEE CALCULATION  1. BASIC FILING FEE  Large Entity Small Entity Fee Fee(s) Fee Fee(s) Fee Description Fee  Code Code Paid  1001 750 2001 375 Utility filling fee  1002 330 2002 165 Design filling fee  1004 750 2004 375 Reissue filling fee  1005 160 2005 80 Provisional filling fee  SUBTOTAL (1) (\$) 160  2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE Fee Extra Claims  Total Claims							
Account Number Deposit Account Name  Seed Intellectual Property Law Group PLLC  The Commissioner is authorized to (check all that apply)  Charge fee(s) indicated below Charge any additional fee(s) during the pendency of this application Charge any deficiencies to the above-identified deposit account.  FEE CALCULATION  1. BASIC FILING FEE Large Entity Fee Fee(\$) Fee Fee(\$) Fee Description Fee Code Code Code Code Code Code Code Co							
Account Name    Seed Intellectual Property Law Group PLLC	Account 19-1090						
Charge fee(s) indicated below  Charge any additional fee(s) during the pendency of this application  Charge fee(s) Indicated below, except for the filling fee  Charge any deficiencies  to the above-identified deposit account.  FEE CALCULATION  1. BASIC FILING FEE  Large Entity Small Entity Fee Fee(\$) Fee Fee(\$) Fee Description Fee Code Code Paid  1001 750 2001 375 Utility filling fee 1002 330 2002 165 Design filling fee 1003 520 2003 260 Plant filling fee 1004 750 2004 375 Reissue filling fee 1005 160 2005 80 Provisional filling fee 1006 SUBTOTAL (1) (\$) 160  2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE Fee Extra from Fee Delay Paid  Total Claims = Fee Fee Fee Fee Fee Fee Fee Fee Fee	Account Seed Intellectual Property Law Group						
Charge any additional fee(s) during the pendency of this application  Charge fee(s) Indicated below, except for the filling fee  Charge any deficiencies to the above-identified deposit account.  FEE CALCULATION  1. BASIC FILING FEE  Large Entity Small Entity Fee Fee(\$) Fee Fee(\$) Fee Description Fee Code Code Paid 1001 750 2001 375 Utility filling fee 1002 330 2002 165 Design filling fee 1003 520 2003 260 Plant filling fee 1004 750 2004 375 Reissue filling fee 1005 160 2005 80 Provisional filling fee 1005 160 2005 80 Provisional filling fee SUBTOTAL (1) (\$) 160  2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE Fee Extra from Fee Claims Fee Claims below Paid  Total Claims = Fee Claims below Paid  Total Claims = Claims in excess of 20 1201 84 2201 42 Independent claims in excess of 3 1203 280 2203 140 Multiple dependent claim, if not paid 1204 84 2204 42 "Reissue claims in excess of 20 and over original patent  SUBTOTAL (2) (\$)	The Commissioner is authorized to (check all that apply)						
Charge fee(s) Indicated below, except for the filling fee  Charge any deficiencies  to the above-identified deposit account.  FEE CALCULATION  1. BASIC FILING FEE Large Entity Small Entity Fee Fee(\$) Fee Fee(\$) Fao Description Fee Code Code Paid  1001 750 2001 375 Utility filing fee 1002 330 2002 165 Design filing fee 1003 520 2003 260 Plant filing fee 1004 750 2004 375 Reissue filing fee 1005 160 2005 80 Provisional filing fee 1006 SUBTOTAL (1) (\$) 160  2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE Fee Extra from Fee Claims Fee Claims below Paid  Independent Claims Fee Foo Foo Claims in excess of 20 1201 84 2201 42 Independent claims in excess of 3 1203 280 2203 140 Multiple dependent claim, if not paid 1204 84 2204 42 "Reissue Independent claims over original patent 1205 18 2205 9 "Roissue Indigendent claims in excess of 20 and over original patent  **Reissue claims in excess of 20 and over original patent  **Reissue claims in excess of 20 and over original patent  **Reissue claims in excess of 20 and over original patent  **Reissue claims in excess of 20 and over original patent	Charge fee(s) indicated below Credit any overpayments						
Charge fee(s) Indicated below, except for the filling fee  Charge any deficiencies  to the above-identified deposit account.  FEE CALCULATION  1. BASIC FILING FEE Large Entity Small Entity Fee Fee(\$) Fee Fee(\$) Fao Description Fee Code Code Paid  1001 750 2001 375 Utility filing fee 1002 330 2002 165 Design filing fee 1003 520 2003 260 Plant filing fee 1004 750 2004 375 Reissue filing fee 1005 160 2005 80 Provisional filing fee 1006 SUBTOTAL (1) (\$) 160  2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE Fee Extra from Fee Claims Fee Claims below Paid  Independent Claims Fee Foo Foo Claims in excess of 20 1201 84 2201 42 Independent claims in excess of 3 1203 280 2203 140 Multiple dependent claim, if not paid 1204 84 2204 42 "Reissue Independent claims over original patent 1205 18 2205 9 "Roissue Indigendent claims in excess of 20 and over original patent  **Reissue claims in excess of 20 and over original patent  **Reissue claims in excess of 20 and over original patent  **Reissue claims in excess of 20 and over original patent  **Reissue claims in excess of 20 and over original patent	Charge any additional fee(s) during the pendency of this application						
Total Claims	П						
Total Claims	X Charge any deficiencies						
1. BASIC FILING FEE   Large Entity   Small Entity   Fee	to the above-identified deposit account.						
1. BASIC FILING FEE   Large Entity   Small Entity   Fee							
Large Entity   Small Entity   Fee	FEE CALCULATION						
Fee	<del></del>						
Code							
1001   750   2001   375   Utility filing fee   1002   330   2002   165   Design filing fee   1003   520   2003   260   Plant filing fee   1004   750   2004   375   Reissue filing fee   1005   160   2005   80   Provisional filing fee   160	The second secon						
1002   330   2002   165   Design filing fee   1003   520   2003   250   Plant filing fee   1004   750   2004   375   Reissue filing fee   160   1005   160   2005   80   Provisional filing fee   160   160   2005   80   Provisional filing fee   160   160   2005   80   Provisional filing fee   160   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   2005   200							
1003   520   2003   250   Plant filing fee   1004   750   2004   375   Reissue filing fee   160   160   2005   80   Provisional filing fee   160   SUBTOTAL (1)   (\$) 160    2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE   Fee   Extra from Fee   Delay   Paid   Fee							
1004   750   2004   375   Reissue filing fee   160	Too Dolg, Ming 100						
1005   160   2005   80   Provisional filing fee   SUBTOTAL (1)   (\$) 160	, in the state of						
Subtotal (1)   (\$) 160	1005 160 2005 80 Provisional filing						
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE  Fee Extra from Fee Claims below Paid  Total Claims =							
Total Claims	SUBTOTAL (1) (\$) 160						
Extra   from   Fee   Paid							
Total Claims							
Total Claims							
Independent   Claims	Total Claims						
Claims	<u></u> <u></u> <u></u>						
Largo Entity   Small Entity   Fee   Fee   Fee   Fee   Code   (\$)   Code   C							
Fee   Fee   Fee   Fee   Fee   Fee   Fee   Fee   Code   S							
Code   (\$)   Code   (\$)   Fee Description							
1202   18   2202   9   Claims in excess of 20	Fee Description						
1201   84   2201   42   Independent claims in excess of 3   1203   280   2203   140   Multiple dependent claim, if not paid   1204   84   2204   42   ** Reissue independent claims over original patent   1205   18   2205   9   ** Reissue claims in excess of 20   and over original patent   SUBTOTAL (2)   (5)	2020 (3) 0040 (4)						
1203 280 2203 140 Multiple dependent claim, if not paid 1204 84 2204 42 "Reissue independent claims over original patent 1205 18 2205 9 "Reissue claims in excess of 20 and over original patent  SUBTOTAL (2) (S)							
1204 84 2204 42 "Reissue Independent claims over original patent  1205 18 2205 9 "Reissue claims in excess of 20 and over original patent  SUBTOTAL (2) (\$)	, and the second of the second						
1205 18 2205 9 ** Reissue clalms in excess of 20 and over original patent  SUBTOTAL (2) (\$)	** Deireue Independent einime ever						
and over original patent  SUBTOTAL (2) (S)							
<u> </u>							
**or number proviously paid, if greater, For Reissues, see above	SUBTOTAL (2) (\$)						
	**or number proviously paid, if greater, For Reissues, see above						

ittorney Di	DCKEL NO	0.	4007	J.463F I		
			FFF C	ALCULATION (continued)		
3. ADDIT	TIONAL	FEES	1 22 07	ALCOLATION (LOTHINGLY)		
Large E		<u>\$m</u>				
Fee Code	Fce (\$)	Fec Code	Fee (\$)	Fee Description	Foo Paid	
1051	130	2051	65	Surcharge - late filing fee or oath		
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.		
1053	130	1053	130	Non-English specification		
1812	2520	1812	2520	For filing a request for ex parte reexamination		
1804	920	1804	920*	Requesting publication of SIR prior to Examiner action		
1805	1840°	1805	1840*	Requesting publication of SIR after Examiner action		
1251	110	2251	55	Extension for reply within first month		
1252	410	2252	205	Extension for reply within second month		
1253	930	2253	465	Extension for reply within third month		
1254	1450	2254	725	Extension for reply within fourth month		
1255	1970	2255	985	Extension for reply within fifth month		
1401	320	2401	160	Notice of Appeal		
1402	320	2402	160	Filing a brief in support of an appeal		
1403	280	2403	140	Request for oral hearing		
1451	1510	1451	1510	Petition to institute a public use proceeding		
1452	110	2452	55	Petition to revive - unavoidable		
1453	1300	2453	65 <b>0</b>	Petition to revive - unintentional		
1501	1300	2501	650	Utility Issue fee (or reissue)		
1502	470	2502	235	Design issue fee		
1503	630	2503	315	Plant issue fee		
1460	130	1460	130	Petitions to the Commissioner		
1807	50	1807	50	Processing fee for provisional applications		
1806	180	1806	160	Submission of Information Disclosure Stmt		
8021	40	8021	40	Recording each patent assignment per property (times number of properties)		
1809	750	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))		
1810	750	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))		
1801	750	2801	375	Request for Continued Examination (RCE)		
1802	900	1802	900	Request for expedited examination of a design application		
Other lee	Other fee (specify)					
*Reduce	d by Bas	ilc Fillag	Fee Pa	did SUBTOTAL (3) (\$)		

Name (Print/Type)	Karl R. Hermanns		ation No. 33,507	
Firm Name/ Addross	V 81			00500
Signature	9.44	Dato	June 12, 2003	PATENT TRADEMARK OFFICE
D:\740073.4	65P1 \390421_4'.DOC		<del>• • • • • • • • • • • • • • • • • • • </del>	

## **APPLICATION DATA SHEET**

Secrecy Order in Parent Appl.?::

## **Application Information**

Application number::	, in the second
Filing Date::	
Application Type::	Regular
Subject Matter::	Provisional
Suggested classification::	
Suggested Group Art Unit::	
CD-ROM or CD-R?::	None
Number of CD disks::	
Number of copies of CDs::	
Sequence submission?::	
Computer Readable Form (CRF)?::	No
Number of copies of CRF::	•
Title ::	METHOD AND APPARATUS FOR
	CHARACTERIZATION OF INTERACTIONS
Attorney Docket Number::	740073.465P1
Request for Early Publication?::	No
Request for Non-Publication?::	No
Suggested Drawing Figure::	
Total Drawing Sheets::	10
Small Entity?::	No
Petition included?::	No
Petition Type::	
Licensed U.S. Gov't Agency::	
Contract or Grant No.	

No

#### **First Applicant Information**

Applicant Authority Type:: Inventor

Primary Citizenship Country:: Sweden

Status:: Full Capacity

Given Name:: Karl

Middle Name::

Family Name:: Andersson

Name Suffix::

City of Residence:: Uppsala

State or Province of Residence::

Country of Residence:: Sweden

Street of mailing address:: Ulleråkersvägen 62

City of mailing address:: Uppsala

State or Province of mailing address::

Country of mailing address:: Sweden

Postal or Zip Code of mailing address:: SE-756 43

#### **Second Applicant Information**

Applicant Authority Type:: Inventor

Primary Citizenship Country:: Sweden

Status:: Full Capacity

Given Name:: Christina

Middle Name::

Family Name:: Wass

Name Suffix::

City of Residence:: Uppsala

State or Province of Residence::

Country of Residence:: Sweden

Street of mailing address:: Norrtäljegatan 24

State or Province	e of mailing address::						
Country of mailin	g address::	Swe	den				
Postal or Zip Code of mailing address::		SE-753 27					
Correspondenc	e Information						
Correspondence	Customer Number ::	005	00				
Representative	Information						
Representative	Customer Number::				00500		
Domestic Priori	·		;				
Application ::	Continuity Type::	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Parent Application:	:	Parent Filing Date::		
					·		
			,				
			J		···		
			•				
					•		

Uppsala

City of mailing address::

## **Foreign Priority Information**

Country::	Application number::	Filing Date::	Priority Claimed::
	1		
		·	<u>.</u>

## **Assignee Information**

Assignee name::	Biacore AB
Street of mailing address::	Rapsgatan 7
City of mailing address::	Uppsala
State or Province of mailing address::	
Country of mailing address::	Sweden
Postal or Zip Code of mailing address::	S-754 50

## METHOD AND APPARATUS FOR CHARACTERIZATION OF INTERACTIONS

#### BACKGROUND OF THE INVENTION

#### Field of the Invention

5

10

25

The present invention relates generally to analysis methods wherein it is desired to determine characteristics, such as kinetic properties or affinity for various interactions in multi-component systems. In particular it relates to methods for the analysis of interactions between species in a liquid environment, such as a compound and a target. The invention also relates to the analysis of site specific binding between species, *e.g.*, compounds and targets. More in particular it relates to a method and apparatus for determining kinetic properties or affinity by providing a pulsed gradient of a sample containing a compound of interest, whereby the target molecule is exposed to the gradient of the compound with which it can interact, and detecting a result of said interaction.

#### Description of the Related Art

In the study of candidates for new drugs (screening) it is often the case that substances exhibiting weak binding are encountered, leading to rapid events, exhibiting small time constants. Surface Plasmon Resonance (SPR) is a powerful technique for the study of affinity between substrates and targets, but typically designed for slower events. Instruments utilizing the principle of SPR (e.g., the instruments supplied by the applicant of the present invention, Biacore AB, Uppsala, Sweden) measure changes in refractive index of the medium next to a sensor chip, resulting from altered mass concentration at the surface.

In conventional SPR assays (e.g., using the systems from Biacore AB, Uppsala, Sweden), one sample injection corresponds to one concentration of the selected compound, and the injection comprises one single segment or "plug" of sample liquid. In most cases of kinetic and affinity determination, a few injections of different concentration

are sufficient to obtain reliable results of interaction rate or strength (i.e., association rate constant, dissociation rate constant and dissociation constant). However, when studying molecules with low affinity or exhibiting fast kinetics, many such measurements need to be performed. This is a relatively time-consuming process, with considerable sample losses. With the injection exhibiting the highest precision of the available injection methods, every injection requires 40 µl of sample in addition to the desired injection volume to prevent dispersion with buffer.

In an article by Shan-Retzlaf et al, in *Analytical Chemistry*, Vol. 72, No. 17, pp. 4212-4220, entitled "Analyte Gradient-Surface Plasmon Resonance: A One-Step Method for Determining Kinetic Rates and Macromolecular Binding Affinities", a method for determining kinetic rates and equilibrium binding affinities using SPR is disclosed.

It is a one-step method making use of a gradient such that under continuousflow conditions, the concentration of compound to be analyzed passing over the sensor surface increases linearly with time. The rate at which analyte binds to the immobilized receptors is measured by monitoring the change in the surface plasmon resonance minimum as the analyte concentration increases. Kinetic rates are determined by fitting data to a modified version of a two-compartment model.

Although representing an improvement, it still suffers from a lack of capability to perform measurements on systems exhibiting relatively fast kinetic behaviour, and also in that relatively large sample quantities are needed for a full titration.

#### BRIEF SUMMARY OF THE INVENTION

15

20

25

The disadvantages with the prior art methods are overcome with the present invention, in a method for the characterization of interaction between at least two species in a liquid environment, such as the affinity and/or kinetic properties and/or the assay conditions, as defined in claim 1.

Thereby, a concentration gradient of at least a first one of said species is generated, and the gradient is passed through a sensor device. A result of an interaction between said at least two species is detected by said sensor device. Before passing the

liquid flow through the sensor device, the flow of liquid is intersected at least once with an additional liquid, so as to create at least two separated segments of liquid.

In this way, the amount of sample needed for the measurement is considerably reduced, and the time required for a completed measurement is also considerably reduced.

5

10

15

In one embodiment of the invention one compound to be studied and one target is used. This would be the most frequently used method of studying individual compounds/substances.

In another embodiment a sample liquid is employed, comprising two or more compounds, one of which has known binding characteristics and constitutes the sample gradient, the characteristics of the other compound(s) being unknown. This embodiment is employed to assess information of the strength of the binding of the compound(s) having unknown characteristics, and to decide whether the compound binds to the same site on the target molecule or not.

In a further embodiment, the compound of interest is an enzyme reacting with a substrate.

In still another embodiment the gradient can be used for improving assay conditions, as exemplified by finding optimal conditions (concentration or pH) for the regeneration of a sensor surface (i.e., to remove compound from target).

In a further aspect of the invention there is provided an apparatus for the characterization of interaction, such as the affinity and/or kinetic properties and/or the assay conditions, of at least one compound in solution interacting with at least one target, as defined in claim 26.

The apparatus is suitably run under the control of software in the form of a computer program product directly loadable into the internal memory of a processing means within or associated with the apparatus, and comprising the software code means for performing the steps of the method according to the invention.

The software can also be in the form of a computer program product stored on a computer usable medium, comprising a readable program for causing a processing

means in the apparatus to control an execution of the steps of the method according to the invention.

#### BRIEF DESCRIPTION OF THE DRAWINGS

The invention will be described in detail below with reference to the following drawings.

Figure 1 shows schematically a system for performing the method according to the invention;

Figure 2 illustrates a non-equilibrium state in a pulse injection according to the invention;

Figure 3 is a typical sensorgram representing mass concentration near the surface as a function of time obtained with one embodiment of the method according to the invention;

Figure 4 illustrates a dual gradient;

Figure 5 shows responses of individual samples and the response of mixed samples of phenylbutazone and warfarin;

Figure 6 shows responses of individual samples and the response of mixed samples of digitoxin and warfarin;

Figure 7 illustrates the sum of added responses and the response of a mixture of digitoxin and warfarin;

Figure 8 illustrates a set up for a case where the injections comprise alternating pulses of three different liquids;

Figure 9 illustrates a response curve for a case where three pulsed injections are employed; and

Figure 10 illustrates an alternative method of creating a gradient.

### 25 DETAILED DESCRIPTION OF THE INVENTION

15

For the purpose of the present invention the following terms and expressions should be taken to have the indicated meanings:

15

20

25

For the purpose of this application, a "species" is any entity such as a molecule, a compound, substance, antibody, antigen, cell, cell fragment, or any other moiety that can be provided in a liquid environment. In order to be detectable, it should preferably be capable of some sort of interaction with another species, a result of the interaction being detectable by some means. However, of course in certain instances an analyte maybe does not interact with another species of interest, and thus no explicit result of interaction can be measured, but this lack of result is also detectable, and therefore this kind of non-interacting species is also included in the definition of species.

"Injection" is the delivery of at least a part of an amount of liquid into a 10 flow cell or the like of an analysis instrument.

A "pulse" is a fraction of an injection, i.e., a segment of the injected amount of liquid.

A "pulse series" is at least two pulses.

The method according to the invention is usable with a variety of detection systems, including those relying on a label, such as a radiolabel, a chromophore, a fluorophore, marker for scattering light, electrochemically active marker, magnetically active marker, thermoactive marker, a chemiluminescent moiety or a transition metal, as well as so-called label free detection systems.

For many applications, detection is conveniently performed with a chemical sensor or a biosensor, which is broadly defined as a device using a component for molecular recognition (e.g., a layer or pattern with immobilized antibodies) in either direct conjunction with a solid state physicochemical transducer, or with a mobile carrier bead/particle being in conjunction with the transducer. While such sensors are typically based on label-free techniques, detecting e.g., change in mass, refractive index, or thickness for the immobilized layer, there are also sensors relying on some kind of labelling. Typical sensor detection techniques include, but are not limited to, mass detection methods, such as piezoelectric, optical, thermo-optical and surface acoustic wave (SAW) device methods, and electrochemical methods, such as potentiometric, conductometric, amperometric and capacitance/impedance methods. With regard to optical detection methods, representative

15

20

methods include those that detect mass surface concentration, such as reflection-optical methods, including both internal and external reflection methods, angle, wavelength, polarization, or phase resolved, for example ellipsometry and evanescent wave spectroscopy (EWS), both may include surface plasmon resonance (SPR) spectroscopy, Brewster angle refractometry, critical angle refractometry, frustrated total reflection (FTR), evanescent wave ellipsometry, scattered total internal reflection (STIR), optical wave guide sensors, evanescent wave-based imaging such as critical angle resolved imaging, Brewster angle resolved imaging, SPR angle resolved imaging, and the like. Further, photometric and imaging/microscopy methods based on for example surface enhanced Raman spectroscopy (SERS), surface enhanced resonance Raman spectroscopy (SERS), evanescent wave fluorescence (TIRF) and phosphorescence may be mentioned, as well as waveguide interferometers, waveguide leaking mode spectroscopy, reflective interference spectroscopy (RIfS), transmission interferometry, holographic spectroscopy, and atomic force microscopy (AFR).

The invention is illustrated in the examples mainly with the use of SPR, which should not be taken to be limiting on the scope of the invention.

First a brief description of the SPR technique as used in the Biacore systems will be given.

In SPR, changes in refractive index of the medium next to a sensor chip, resulting from altered mass concentration at the surface are measured. The signal is measured in response units, RU, 1,000 RU corresponding to an approximate surface concentration of 1 ng/mm², and graphically presented as a function of time in a sensorgram. In the terminology for the purpose of this application, the molecule attached to a surface is referred to as the target, whereas the compound to be analyzed is the molecule in solution. The solution containing the compound is injected over a surface, the sensor chip, typically coated with a carboxymethyl-dextran matrix, and transported by a continuous flow. The process is driven by a system of two automated pumps, one of which maintains a constant buffer flow and the other controls injection.

Target is covalently bound to the sensor chip matrix in a process called immobilisation. The most commonly used immobilisation technique is amine coupling, in which reactive esters are introduced into the surface matrix by modification of the carboxymethyl groups. These esters then react spontaneously with amines and other nucleophilic groups on the target to form covalent links. There are other ways besides amine coupling to link target to the matrix. For example, the so-called "ligand thiol coupling" method introduces a reactive disulphide group on to carboxyl groups of the sensor chip matrix, which are exchanged with intrinsic thiol groups of the target.

The covalent coupling withstands conditions that break the bonds between target and compound, a process called regeneration. The same surface can therefore be used several times.

During injection, compound molecules are continuously transported to the surface, and allowed to associate with target molecules. When the injection stops, the buffer flow washes off dissociated compounds. The association phase is described by (for 1:1 binding)

$$dR/dt = k_a C(R_{max} - R) - k_d R$$
 (1)

At equilibrium the response is obtained as

$$R_{eq} = k_a C R_{max} / (k_a C + k_d) \quad (2)$$

20 and during dissociation as

10

15

$$dR/dt = -k_dR_0 (3)$$

where R signifies the response at any time t,  $R_{eq}$  the response at equilibrium,  $R_0$  the response at the end of an injection, and  $R_{max}$  the maximum binding capacity of the surface in RU. C is the molar concentration of the compound of interest.

Figure 1 illustrates schematically a system for performing a method using the principle of the pulse injection according to the invention, in an embodiment in the form of a set up with one sample liquid (exhibiting a gradient) and one buffer. It comprises a measurement system, which for the purpose of this invention comprises tubings, pumps, valves and sensors in which the liquids to be characterized flow. At least one compound is

passed as a flow through the measurement system, and the interaction takes place within said measurement system. There are means, comprising valves, pumps and a control unit for generating a concentration gradient of at least a first one of said compounds. A sensor device capable of detecting a result of an interaction between at least said first compound and another species is provided, suitably as a flow cell. The pumps and/or valves are used for passing said flow through said sensor device, and for intersecting the flow of liquid at least once with a further liquid before the flow is passed through said sensor, so as to create at least two separated segments of liquid containing the compound of interest, under the control of the control unit.

Thus, the apparatus is run under the control of software in the form of a computer program product directly loadable into the internal memory of a processing means coupled to the apparatus. The program comprises the software code means for performing the steps of the method according to the invention.

10

15

20

25

The software can also be in the form of a computer program product stored on a computer usable medium, comprising a readable program for causing a processing means in the apparatus to control an execution of the steps of the method according to the invention.

The pulse injection method according to the present invention has two main features. Firstly, each injection contains a number of short sample pulses, suitably 4 or 5 up to 40 pulses, preferably 15-30, more preferably approximately 20 pulses, generated by an alternating sample and buffer flow, and each pulse preferably has a volume of 10-40µl, preferably 15-25µl, suitably about 20µl. The duration of the pulses, *i.e.*, each segment of solution can be 8-20, preferably about 10-15, suitably 12 seconds long, and the flow rate for the sample liquid through the flow cell may be 50-200, preferably 80-120, suitably 100µl/min.

In contrast, the conventional prior art method consists of one pulse (per injection; the entire injection is one pulse). Secondly, there is provided a concentration gradient combined with pulse injections, which taken together generate information from several concentration levels in a single injection, in that each pulse of the injection in

15

20

25

principle constitutes one concentration. The gradient is produced when buffer and sample are allowed to mix in the tubing during sample aspiration as described below. It should also be noted that some pulses during one injection can be discarded, whereby the discarded segments will not be passed through the sensor. Alternatively, some aliquot(s) of liquid can be discarded even before performing the alternating buffer injections to create the separated segments.

We refer now to Figure 1, which is a schematic illustration of a system embodying the invention and showing the flow paths, for a description of the basic principle of the method according to the invention.

As can be seen in Figure 1, there are provided two vessels (e.g., test tubes) containing sample and buffer, respectively. There is also provided a means for aspirating liquid from the test tubes, indicated with vertical lines extending down into the test tubes. This means can suitably be a needle, and since the same needle is used for both liquids, the needle shown in the buffer tube is shown by a broken line. The needle would thereby be physically moved between the tubes for the aspiration of liquids sequentially. Of course there are other possibilities of devising the aspiration means, the one shown being only exemplary.

A system buffer supply is also provided. Initially the entire system is filled with buffer, i.e., all tubing contains this buffer. The respective segments of tubing (sample and system buffer, respectively) are coupled to an Integrated Fluidic Cartridge (IFC), a device enabling controlled liquid delivery to one or more flow cells. Each flow cell has a sensor surface onto which on or more suitable target(s) are immobilized. There are also provided a number of valves in the IFC for the control of the flows of the respective liquids. Alternatively, the flow in the various lines can be controlled by accurate pumps, whereby the actual flow rates can be monotonically controlled to provide the desired flow rates, ranging from zero flow to the maximum flow rates required, or combinations thereof.

The first step in the procedure is to aspirate a small volume of buffer into the needle, i.e., to immerse the needle into the buffer tube, and to aspirate the appropriate volume into the needle. It is however not strictly necessary to fill the needle with buffer by

10

15

aspiration. Instead, the needle can be filled with buffer from the other end, *i.e.*, from the system buffer supply by filling the entire system with buffer. Then, the needle is moved to the sample tube and a suitable volume of sample of about 500µl is aspirated. However, the actual volume may depend on the application and the kind of sample, and can vary within wide limits, say between 1µl and 4ml.

The aspiration of sample will lead to mixing of the sample and buffer by dispersion, thereby creating a gradient in the tubing. In this case the gradient will be a gradient running through the flow cell. If an increasing gradient is the sample required, one would have to aspirate buffer after the sample aspiration, and ensure that a non-dispersed sample trailing edge is provided by first aspirating an air bubble to protect the sample from liquid already present in the needle, second a sample and third a buffer segment. The aspiration sequence always ends with aspiration of one or a few air bubbles to protect the gradient from liquid already present in the IFC.

Prior to the first step, it is preferable to perform a few alternating air and sample aspirations to provide consecutive segments of air and sample and to inject them into the IFC. In this way the sample will be protected from unwanted dispersion with running buffer in the IFC, *i.e.*, the leading front of the aspirated sample liquid will exhibit the nominal (maximum) concentration.

When a gradient has been established, valves v2 and v3 in the sample and buffer flow lines are opened and closed according to a programmed sequence to enable alternating sample (exhibiting a gradient in the longitudinal direction of the tubing) and buffer pulses to be fed into the flow cells, such that the sample liquid flow is intersected at least once, preferably a plurality of times, by a further liquid, represented by the system buffer in this case. This intersection will create at least two separated segments of liquid.

However, other further liquids than the system buffer are of course possible, such as pure solvent, solutions containing other species of interest, etc.

Thus, the leading edge of a decreasing sample gradient flow will represent a first concentration. Most often the concentration at the leading edge will be very close to the nominal, and can be taken to represent a known concentration. However, the major

15

20

25

part of the sample flow will exhibit a gradient, and thus the majority of said segments that are created, will have different concentrations with respect to said compound.

After a predetermined volume of sample gradient flow has passed into the flow cells, valve v2 is closed and valve v3 is opened, thereby injecting buffer into the line behind the sample flow. During the passage of sample over the sensor surface having targets immobilized on it, the sample will associate with the targets. The volume of sample should preferably be sufficient to enable equilibrium to establish. However, it is not always required that equilibrium be reached. As an example, Figure 2 illustrates a non-equilibrium state, but an equilibrium level can be calculated from the graph. The time frames involved depend on sample specific binding and transport characteristics, flow rate, temperature, flow cell dimensions, etc.

When compound has been injected for a sufficiently long time, buffer is injected by opening valve v3 and closing valve v2. During the passage of buffer over the surface, sample will dissociate. The process is repeated until the aspirated sample has been injected.

It is not necessary to inject the complete gradient into the flow cell. During buffer injection (v3 open, v2 closed) valve 1 can be opened to discard a small segment of the gradient. This will reduce the number of pulses produced and reduce the time needed for a full injection.

Figure 3 is a typical example of a sensorgram resulting from a procedure as the one just described.

In one preferred embodiment, wherein a system without valves is used, during the association phase, *i.e.*, during the time the sample is passed through the sensor cell, the buffer flow is set to a very low value, less than 5%, and, *e.g.*, about 1% of the regular flow. This is not strictly necessary, but prevents sample solution from leaking into the buffer line. Then a certain, predetermined amount of sample is injected into the IFC at a specified rate. The buffer flow rate is then reset to the regular rate. During the passage of buffer through the cell, sample compound that has bound to the target on the sensor surface is allowed to dissociate for a suitable time period.

15

20

25

In one embodiment of the invention, the sample gradient can be a "dual gradient". This is accomplished by aspirating two different sample solutions, which when they are mixed in the tubing by dispersion in the same manner as with sample and buffer, produce an increasing gradient of one sample compound and a decreasing gradient of the other sample compound. This kind of gradient can be useful for determining if two samples compete for the same binding site on the target or if they bind to different binding sites on the target. Such information is highly valuable in the drug development process, as it can indicate possible unwanted interactions between drugs in different therapeutic areas.

In a further embodiment of the invention the reaction system to be studied can be an enzyme-substrate interaction. Thereby, an enzyme solution is substituted for the buffer, and a gradient of a suitable substrate for the enzyme is provided by aspiration of a suitable buffer and substrate solution in a manner similar to the principle discussed above.

With reference to Figure 10, an alternative method of creating a gradient is possible by aspirating a sample segment of known concentration and diluting it with buffer in the IFC using a connection c1 and a tubing segment m1. This allows the buffer and sample to form a homogenous mixture prior to contacting the flowcells. The pulses would be generated as previously described, *i.e.*, by using alternating pumps or valves v2 and v3. The connection c1 could be a simple T-connection so that the concentration of the sample in the gradient is controlled by how the ratio of [flowrate (buffer)] and [flowrate (sample)] changes over time. Another possibility could be to have a two-way valve as connection c1. The concentration of the sample will be controlled by switching the inlet to m1 between buffer and sample, having the two-way valve open for buffer a different time than open for sample. In the tubing segment m1 the discrete connected segments of sample and buffer will form a homogenous mix due to dispersion. This method makes it possible to generate a gradient with known concentration of the sample at all times, in contrast to the dispersion concentration gradient where only the first few pulses have a known compound concentration.

The method according to the invention is applicable in a general sense, *i.e.*, for an arbitrary number of sample flows, although practical limitations restrict the actual

number that is possible. If it is desirable to run a plurality of different sample or reagent solutions, a corresponding number of tubings could be provided. Thereby, a plurality of sample and/or other liquids are passed alternatingly according to a predetermined sequence through the measurement system. However, it is also possible to have several components in one gradient, which then would require only one tube. This means that the physical set up may become more complex, but it is still within the inventive concept to devise such systems.

The invention will now be further illustrated by the following non-limiting examples.

#### 10 Examples

20

Several candidate model systems for compound – target were tested for suitable characteristics, such as rapid association and dissociation, as well as sufficient response levels (more than 20 RU).

The pulse injection method was tested on myoglobin – anti-myoglobin to get an idea of what a binding curve from a system with relatively slow kinetics would look like.

Interactions between lysozyme and a camel derived monoclonal antilysozyme antibody served as template for determination of interaction rate constants.

Because of its rapid kinetics the maltose – anti-maltose system was used for steady state studies, in which equilibrium response levels are used to estimate affinity (K<sub>D</sub>).

Competitive inhibition was investigated using the pulse injection method on human serum albumine, HSA, and some known binders (drugs).

For all model systems used, 1:1 binding was assumed.

#### Materials and methods

#### 25 Instrumentation and software

The sensor chips that were used throughout were CM-5 surfaces (Biacore AB, Uppsala, Sweden). All interaction studies were performed with a BIACORE® 3000

biosensor (Biacore AB, Uppsala, Sweden). Data was presented as sensorgrams by the BIACORE® 3000 control software and evaluated using the BIAevaluation software, version 3.1 (Biacore AB, Uppsala, Sweden), Matlab version 5.3 (The MathWorks, Inc., Natick, MA) and Excel 97 (Microsoft Corp., Redmond, WA).

#### 5 Reagents

BIA-certified HBS-EP (0.01 M Hepes, pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% Tween 20; Biacore AB, Uppsala, Sweden) was used as running buffer, unless otherwise stated.

Monoclonal anti-myoglobin antibody and sheep myoglobin were from 10 Biacore AB.

The cAb-Lys3:s SGS, camel derived heavy chain triple mutant single domain antibody directed against lysozyme, were obtained from the Department of Ultrastructure, Vrije Universiteit, Brussels, Belgium. Hen egg-white lysozyme was from the same place.

Monoclonal anti-maltose antibody, monoclonal anti-AFP antibody (clone 118B) and maltose were from Biacore AB.

HSA (essentially fatty acid and globulin free, A 3782) as well as warfarin, digitoxin and phenylbutazone were from Sigma.

#### Example 1 (Slow kinetic interaction)

A monoclonal anti-myoglobin antibody was immobilised to a level of approximately 2070 and 930 RU (flowcells 2 and 4, respectively in Figure 1) by standard amine coupling procedure at 20 °C. Following a 7-min. activation with EDC-NHS, anti-myoglobin (10 µg/ml in 10 mM sodium acetate, pH 5.0) was injected over the surface for 5 min. Unreacted esters were then deactivated by a 7-min. injection of 1 M ethanolamine, pH 8.5. Channels 1 and 3 were used as reference cells, and were activated and deactivated as above. The flow rate was 5 µl/min.

Myoglobin, 20 µg/ml (initial concentration 110 nM in running buffer), was injected over all flowcells simultaneously at 20, 25 and 30 °C, using the pulse injection

10

15

method. The signals in flowcells 1 and 3 were subtracted from those of flowcells 2 and 4, respectively, to correct for bulk errors. Each injection was followed by two 30-sec. pulses of regeneration solution (10 mM glycine pH 3, 1 mM NaCl, 10 % ethanol). The injection protocol was as follows:

- A few alternating air and sample segments are aspirated and injected into the IFC. In this way the sample will be protected from unwanted dispersion with running buffer in the IFC.
  - 2. The needle is filled with a certain volume of buffer. Sample is then aspirated, which will lead to a rapid mixing of the sample and buffer by dispersion. Depending on the time between aspiration and injection, diffusion probably also influences the sample concentration to some extent, although the contribution is minor.
  - 3. The valves of the sample and buffer flow are opened to enable alternating sample and buffer pulses. Figure 1 shows a schematic view of the flow paths. During the association phase (here 12 seconds) buffer flow is set to 1 μl/min, and a certain amount of sample (here 20 μl) is injected into the IFC (disp) at a specified rate, here 100 μl/min. The flow rate is then reset to 100 μl/min and the compound that has associated is allowed to dissociate for 12 seconds. The process is repeated until the entire aspirated sample has been injected.

The signals of the reference flowcells were subtracted from the response curves of the anti-myoglobin cells.

The binding curve of the pulse injections of myoglobin performed on the anti-myoglobin surface (Figure 2) at three different temperatures corresponded well with the curve that was obtained from the computer simulations.

### 25 Example 2 (Estimation of interaction rate constants)

The kinetics of the triple mutant of the camel antibody (SGS) binding to lysozyme was studied with the pulse injection method according to the invention. All experiments were performed at 30 °C. 190 RU (chip 1) and 280 RU (chip 2) of lysozyme

. 10

15

20

was immobilised using amine coupling procedure. Upon a 2-min. activation, lysozyme (8 μg/ml in 10 mM Na<sub>2</sub>HPO<sub>4</sub>, pH 7.0) was injected for 3 min. (chip 1) and 4 min. 30 sec. (chip 2). 10 mM Na<sub>2</sub>HPO<sub>4</sub>, pH 7.0 (flow rate 5 μl/min) was used as running buffer during immobilisation. SGS were injected at different initial concentrations (0.5, 1.0 and 2.0 μM in HBS-EP). Results are shown in Figure 3.

Bulk errors in the sample solutions were corrected for by subtraction of the reference flow cell signals. Individual pulses were separated and aligned, using MATLAB, so that each pulse corresponded to one binding curve. The curves were superimposed in the BIAevaluation software. 15 pulses were used in every fit. The first two pulses were assumed to be of initial concentration. Global starting values of  $k_a$ ,  $k_d$  and  $R_{max}$  were fitted to the second pulse (pulse number one was omitted because of its irregular shape), since its concentration was known. These values were then used to locally fit the concentrations of all pulses.  $k_a$ ,  $k_d$  and  $R_{max}$  estimations were refined, using the new concentration information. The process was repeated until all parameters converged. Each pulse injection was evaluated separately. The fitting of the concentration resulted in a partially linear concentration gradient. Kinetic data obtained with the pulse injection method is presented together with mean values and standard deviations in Table 1 (SGS).

Table 1

(Results from a pulse injection assay with camel antibody SGS and lysozyme)

	C <sub>0</sub>	$k_a (M^{-1}s^{-1})$	k <sub>d</sub> (s <sup>-1</sup> )	R <sub>max</sub> (RU)	K <sub>D</sub> (M)	χ² **)
	$(\mu M)^{*)}$					"
Chip 1	0.5	1.75e5	0.508	137	2.9e-6	0.0972
(190 RU)	0.5	9.99e4	0.435	180	4.35e-6	0.151
	0.5	1.17e5	0.484	170	4.14e-6	0.122
	1	1.91e5	0.475	112	2.5e-6	0.243
	1	4.6e5	0.514	72.7	1.12e-6	0.198
	1 .	1.62e5	0.513	126	3.17e-6	0.325
Chip 2	1	4.60e5	0.466	119	1.01e-6	0.383
(280 RU)	1	1.11e5	0.462	286	4.15e-6	0.374
	1	1.32e5	0.42	251	3.19e-6	0.348
	2	1.87e5	0.487	188	2.60e-6	1.53

	2	2.41e5	0.464	151	1.93e-6	0.816
	2	2.79e5	0.421	137	1.51e-6	1.85
Average:		2.18e5	0.471	133 189	2.71e-6	
St.dev:		1.25e5	0.033	39.3 66.8	1.16e-6	
Rel. st.dev.:		57 %	7 %	30 % 35 %	43 %	

#### Example 3 (Estimation of affinity)

5

Approximately 15000 RU of anti-maltose antibody was immobilised in one of the four flowcells. Roughly the same amount of another antibody, anti-AFP, was immobilised in a reference flowcell in order to minimise errors in reference subtraction due to the high immobilisation level. These two proteins were immobilised using the "amine coupling" procedure as follows: HBS-EP was used as running buffer with a constant flow rate of 5 µl/min. After activation for 12 min. with EDC, target (anti-maltose or anti-AFP, 50 μg/ml in 10 mM sodium acetate, pH 5.0) was injected for 7 min., followed by a 12-min. deactivation. Immobilisation and all measurements on the surface were performed at 25 °C.

Samples of different initial concentrations (0.05 and 0.1 mM) were injected over the surface. The association and dissociation phases of each pulse were 12 seconds. 15 This should was sufficient to reach an equilibrium level and to allow the complexes to completely dissociate. Each experiment started with a blank run, i.e., a series of pulses of running buffer alone. The concentration of the first pulse, C1, was assumed to be equal to the concentration in the vial. The refractive index of maltose being relatively high, 20 concentrations of the following pulses, Ci, could be estimated from the response in the reference flowcell as:

$$C_i = R_{eq(i)}/R_{eq(1)} \cdot C_1 \tag{4}$$

Data from the sensorgrams were extracted from the BIACORE result files in the same way as the camel antibody pulses. Response levels were obtained by taking the

<sup>\*)</sup>  $C_0$  is the nominal concentration of SGS \*\*)  $\chi^2$  is a statistical measure of the quality of the fit

15

20

25

average of 10 data points at equilibrium. Evaluation was performed with the BIAevaluation software. The affinity constant,  $K_A$ , was obtained as the negative slope in a linearly fitted  $R_{eq}/C$  versus  $R_{eq}$  plot (analogous to a Schatchard plot).  $K_D$  was obtained as  $1/K_A$ .  $R_{max}$  was found from the interception with the x axis. The constant multiconcentration pulse series were evaluated with a non-linearly fitted  $R_{eq}$  versus C plot, whereby  $K_A$ ,  $K_D$  and  $R_{max}$  values were obtained directly from the software.

In order to compare the results obtained with pulse injections to results obtained with the conventional method, 12 maltose injections of concentrations ranging from 0 to 1500  $\mu$ M were performed. The injection time was 15 sec. Data was evaluated from a  $R_{eq}$  versus C plot using the BIAevaluation software.

Affinity calculated from data obtained with the pulse injection method according to the invention yielded an average  $K_D$  of 90 x 10<sup>-4</sup> M. A conventional affinity assay yielded a  $K_D$  of 85 x 10<sup>-4</sup> M.

#### Example 4 (Site availability of drugs binding to HSA)

HSA (15 µg/ml in sodium acetate, pH 5.2) was immobilised to a level of approximately 12200 RU, using a standard amine coupling (Frostell-Karlsson et al, J. Med. Chem. 2 000, 43:1986-2000). A neighbouring flowcell was activated and deactivated, and used as reference. The newly immobilised surface was conditioned with three consecutive 30-sec. injections of 50 mM NaOH. The immobilisation and all measurements performed on the surface were carried out at 25 °C.

100 mM (phenylbutazone, digitoxin) and 10 mM (warfarin) stock solutions of compounds in 100 % DMSO were diluted 67 mM isotonic phosphate buffer (9.6 g Na<sub>2</sub>HPO<sub>4</sub>2H<sub>2</sub>O, 1.7 g KH<sub>2</sub>PO<sub>4</sub>, 4.1 g NaCl to 1 litre, pH 7.0) to a DMSO concentration of 5 %. Samples were then diluted in running buffer (67 mM isotonic phosphate buffer, 5 % DMSO, pH 7.4) to an compound concentration of 50 μM.

Equal volumes of two different samples were aspirated from sealed vials without separating air bubbles, and mixed by dispersion in the tubing. The presumed concentration distribution in the tubing of the two samples is shown in Figure 4. Sample

was injected using association and dissociation phases of 12 seconds each. Sample combinations are shown in table 2. Every drug was also run once combined with running buffer. Before and after each run a DMSO correction (Frostell-Karlsson *et al.*, supra) was performed in order to compensate for DMSO bulk differences between reference and HSA flowcells.

Equilibrium data from the sample – buffer runs was collected and response levels were added. The sum was compared to the response obtained when the same compounds were injected as a mixture.

10

15

20

5

Table 2
(Combinations of drugs that were used in the HSA assay)

· · · · · · · · · · · · · · · · · · ·	
Sample 1	Sample 2
Phenylbutazone	Buffer
Phenylbutazone	Warfarin
Buffer	Warfarin
Digitoxin	Warfarin
Digitoxin	Buffer

Equilibrium response levels from the two-sample gradient assay are shown in figures 5 and 6. Figure 7 shows a comparison between added responses from individual samples (X+Y) and responses of the samples injected as a mixture (XY). Digitoxin (D) and warfarin (W) are non-competitive binders. The added responses of individual samples and the response of the mixed samples should therefore be identical (Figure 6). On the contrary, added responses of individual samples should be higher than the response from the samples injected as a mixture in the case of phenylbutazone and warfarin, since they compete for the same site (Figure 5).

25

#### Example 5 (Determination of optimal regeneration conditions)

A problem often encountered in SPR analysis is to determine the optimal regeneration conditions. A too weak regeneration will not restore the sensor chip to a sufficient degree, and a too strong regeneration will destroy the sensor chip. Therefore, it is desirable to be able to optimize the regeneration in a reliable and quick procedure. This can be done with the pulse injection method according to the invention.

Figure 8 illustrates a set up for a case where the injections comprise alternating pulses of three different liquids.

Thus, a set up with three different liquid lines is provided, namely a first line for system buffer (HBS buffer), a second line for an antibody (Anti-biotin antibody (Novocastra Laboratories Ltd, Newcastle upon Tyne U.K.)) and a third line for regeneration solution (50mM NaOH or 10mM Glycin pH 3.0 (both from Biacore AB). The sensor chip is Sensor Chip Biotin (Biacore AB).

The injection sequence was as follows: buffer - antibody - buffer - regeneration(gradient) - buffer - and so on. Two experiments were performed, the results of which are shown in Figure 9: First with a gradient of water and NaOH (broken curve), second with a gradient of water and Glycine (solid curve).

For NaOH, the first (most diluted) regeneration pulse, no regeneration effect 20 is seen. The second pulse gives a significant regeneration, pulses 3 and higher give complete regeneration. For Glycine, no regeneration is seen for any dilution.

### Example 6 (enzyme and substrate interaction)

A set up similar to the one in Figure 1 is employed, but the sample line is used for providing a gradient of the enzyme MAPK2, and the buffer is substituted for a solution comprising myelic basic protein as a substrate for the enzyme. A BIACORE sensor or a spectrophotometer is used to detect the product (phosphorylated myelic basic protein) of the enzymatic action, or the decrease in myelic basic protein concentration.

20

The dual gradient is achieved by filling a needle with a suitable dilution solution such as a buffer containing substrate, and then aspirating enzyme solution. Dispersion will then create a gradient in the same manner as previously described.

A pulse sequence similar to the one used in the discussion of Figure 1 is 5 used.

In this application a new injection method has been disclosed. It is usable for the study of affinity, kinetics and site specificity.

The above examples confirm the working of the present invention.

The average of the K<sub>D</sub> values for the maltose – anti-maltose interaction produced by the pulse injection method with sample dispersion closely resembles the average K<sub>D</sub> estimated with the traditional method.

The prior art method and the methods according to the invention result in comparable, and relatively low, standard deviations in  $k_d$ . The average  $k_a$  and  $k_d$  are in the same range for both methods.

One major advantage of the pulse injection method is the low sample consumption. While a conventional kinetic analysis requires several sample aspirations, each of which uses an additional amount of solution, a single aspiration is enough to obtain multiple binding curves with the pulse injection method. Furthermore, a pulse assay takes considerably less time than a conventional assay. One cycle of 20 pulses lasts about 20 minutes, compared to over an hour and a half for a traditional method (for example the conventional maltose assay in Example 3, containing 12 concentrations).

#### CLAIMS

1. A method of characterizing an interaction between at least two species in a liquid environment, wherein a liquid comprising at least one of said species is passed as a flow through a measurement system, and wherein the interaction takes place within said measurement system, the method comprising the steps of:

providing in said flow of liquid, a concentration gradient of at least one of said species;

passing said flow of liquid comprising at least one of said species through a sensor device; and

detecting by said sensor device a result of an interaction between said at least two species;

characterized in that

the flow of liquid comprising said concentration gradient is intersected at least once with an additional liquid before the flow is passed through said sensor, so as to create at least two separated liquid segments having different concentrations of said species forming the concentration gradient.

- 2. The method of claim 1, wherein the affinity and/or the kinetics and/or the assay conditions for the interaction is/are determined.
- 3. The method of claim 2, wherein assay conditions are determined and said other species comprises an agent associated with assay function.
- 4. The method of claim 3, wherein said agent associated with assay function comprises a regenerating agent.
- 5. The method of claim 3, wherein said agent associated with assay function comprises an agent affecting interaction efficiency.

- 6. The method as claimed in any preceding claim, wherein the flow of liquid is intersected more than once so as to create separated segments of liquid.
- 7. The method as claimed in claim 6, wherein at least one of said separated segments is discarded such that it will not be passed through said sensor.
- 8. The method as claimed in any preceding claims, wherein the interaction takes place between said species and a target immobilized on a surface in a flow cell.
- 9. The method as claimed in any preceding claim, wherein the additional liquid is selected form the group consisting of a buffer and a solvent.
- 10. The method as claimed in any preceding claim, wherein the liquid flow is intersected a plurality of times, such as 5-40, suitably 15-30, preferably approximately 20 times.
- 11. The method as claimed in any preceding claim, wherein consecutive segments of air and sample are injected into the sensor device, in order to prevent unwanted dispersion with running buffer to occur in the sensor device.
- 12. The method as claimed in any preceding claim, wherein said additional liquid is allowed to flow through the system at a reduced rate also during the passage of said solution through the sensor device, preferably at a rate of less than 5% of the nominal rate, most preferably less than 1%.
- 13. The method as claimed in any preceding claim, wherein a dual gradient is generated by mixing two different solutions containing different species, whereby a positive (increasing) gradient is formed for one species and a negative (decreasing) gradient is formed for the other species.

- 14. The method as claimed in any of claims 2 13, wherein each segment of solution is 8-20, preferably about 10-15, suitably 12 seconds long.
- 15. The method as claimed in claim 14, wherein each segment preferably has a volume of 10-40µl, preferably 15-25µl, suitably about 20µl.
- 16. The method as claimed in any preceding claim, wherein the flow rate for the liquid through the flow cell is 50-200, preferably 80-120, suitably about 100µl/min.
- 17. The method as claimed in any preceding claim, wherein one or more aliquots of said liquid flow is/are discarded before the flow is intersected by said additional liquid.
- 18. The method as claimed in any of claims 10 17, wherein the majority of said segments will have different concentrations with respect to said species.
- 19. The method as claimed in any preceding claim, wherein the interaction takes place between the species in solution and a species immobilized on a surface in said measurement system.
- 20. The method as claimed in claim 19, wherein the immobilized species is an antibody and the species in solution is/are an antigen to said antibody.
- 21. The method as claimed in claim 19, wherein the immobilized species is an antigen and the species in solution is/are an antibody for said antigen.
- 22. The method as claimed in any of claims 1 18, wherein the interaction takes place between two species in solution.

- 23. The method as claimed in claim 22, wherein one species is an enzyme and another species is a substrate for said enzyme.
- 24. The method as claimed in any preceding claim, wherein a plurality of sample and/or other liquids are passed alternatingly according to a predetermined sequence through said measurement system.
- 25. The method as claimed in claim 24, wherein a first liquid contains a compound binding to a target on a sensor device, and a second liquid is a regeneration solution, and a third liquid comprises a buffer, and wherein the detected result of the interaction is used to determine an appropriate level of regeneration for said sensor device.
- 26. An apparatus for characterizing interaction of between at least two species in a liquid environment, wherein a liquid comprising said at least one species is passed as a flow through a measurement system, and wherein the interaction takes place within said measurement system, comprising

means for generating a concentration gradient of at least a

first one of said species or of at least one other species having an influence on the interaction or on interacted components;

means for passing said flow through a sensor device; and

means for detecting by said sensor device a result of interaction between said at least two species;

characterized by

means for intersecting the flow of liquid comprising said concentration gradient at least once with an additional liquid before the flow is passed through said sensor, so as to create at least two separated liquid segments having different concentrations of said species.


- 27. A computer program product directly loadable into the internal memory of a processing means coupled to apparatus as claimed in claim 26, comprising the software code means for performing the steps of any of claims 1-25.
- 28. A computer program product stored on a computer usable medium, comprising a readable program for causing a processing means coupled to an apparatus as claimed in claim 26, to control an execution of the steps of any of claims 1-25.


#### ABSTRACT

The invention relates to a method of characterizing interaction between two species in a liquid environment, wherein a liquid comprising said at least one species is passed as a flow through a measurement system, and wherein the interaction takes place within said measurement system. The method comprises generating a concentration gradient of at least a first one of said species or of at least one other species having an influence on the interaction or on interacted components. The flow of liquid is passed through a sensor device, and a result of interaction between said at least two species is detected. The flow of liquid is intersected at least once with a further liquid before the flow is passed through said sensor, so as to create at least two separated liquid segments having different concentrations of at least one of said species forming the concentration gradient.

D:\740073.465P1 \390397\_1.DOC


Express Mail No.: EV348171815US
Title: METHOD AND APPARATUS FOR CHARACTERIZATION OF INTERACTION
Inventors: Karl Andersson et al. Serial No. Docket No.: 740073.465P1






Express Mail No.: EV348171815US

Title: METHOD AND APPARATUS FOR CHARACTERIZATION OF INTERACTION
Inventors: Karl Andersson et al. Serial No. Docket No.: 740073.465P1




Express Mail No.: EV348171815US
Tille: METHOD AND APPARATUS FOR CHARACTERIZATION OF INTERACTION Inventors: Karl Andersson et al. Serial No. Docket No.: 740073.465P1




Express Mail No.: EV348171815US


Title: METHOD AND APPARATUS FOR CHARACTERIZATION OF INTERACTION
Inventors: Karl Andersson et al. Serial No. Docket No.: 740073.465P1




Express Mail No.: EV348171815US
Title: METHOD AND APPARATUS FOR CHARACTERIZATION OF INTERACTION
Inventors: Karl Andersson et al. Serial No. Docket No.: 740073.465P1




Express Mail No.: EV348171815US
Title: METHOD AND APPARATUS FOR CHARACTERIZATION OF INTERACTION
Inventors: Karl Andersson et al. Serial No. Docket No.: 740073,465P1





Express Mail No.: EV348171815US
Title: METHOD AND APPARATUS FOR CHARACTERIZATION OF INTERACTION
Inventors: Karl Andersson et al. Serial No. Docket No.: 740073.465P1



Express Mail No.: EV348171815US
Title: METHOD AND APPARATUS FOR CHARACTERIZATION OF INTERACTION
Inventors: Katl Andersson et al. Serial No. Docket No.: 740073.465P1







Express Mail No.: EV348171815US
Title: METHOD AND APPARATUS FOR CHARACTERIZATION OF INTERACTION
Inventors: Karl Andersson et al. Serial No. Docket No.: 740073.465P1

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

△ BLACK BORDERS
☑ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☑ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
☑ LINES OR MARKS ON ORIGINAL DOCUMENT
☑ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
□ OTHER:

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.